Accreditation Information

CME

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CEC designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CPE

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.00 contact hour (0.100 CEUs) of continuing pharmacy education credit (UAN UAN 0245-0000-17-014-L01-P).

CNE

In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is designated for 1.00 contact hour.

Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Other

Creative Educational Concepts, Inc. certifies this activity for 1.00 hour of participation.

Objectives

  1. Examine recent clinical data and ACC/AHA guideline updates regarding the optimal use and duration of dual antiplatelet therapy (DAPT) in acute coronary syndromes (ACS).
  2. Individualize the duration of DAPT following ACS or percutaneous coronary intervention (PCI) by examining patient specific factors to balance ischemic vs. bleeding risk of extended DAPT.
  3. Explore strategies members of the interprofessional healthcare team can employ to improve adherence and long-term persistence to antiplatelet therapies at discharge and beyond.

 

Target Audience

Cardiologists, internal medicine physicians, emergency department physicians, residents/fellows, physician assistants, nurse practitioners, registered nurses, pharmacists, and other healthcare professionals involved in the management of patients with acute coronary syndrome.

Faculty Disclosure

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planner:
Adrienne Matson, PharmD, BCPS – has no relevant financial relationships to disclose in relation to the content of this activity.

Content Development Faculty:
Tracy Y. Wang, MD, MHS, MSc – has disclosed that she is a consultant for Gilead, Merck, and Sanofi and receives grant/research to her institute, Duke Clinical Research Institute, from AstraZeneca, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Lilly, Gilead Sciences, Novartis, Pfizer, and Regeneron, Dr. Wang herself has received grant/research support from AstraZeneca, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Gilead Sciences, Lilly, Novartis, Pfizer, and Regeneron.
Tracy E. Macaulay, PharmD, BCPS (AQ Cardiology) – has no relevant financial relationships to disclose in relation to the content of this activity.
Kim Newlin, RN, CNS, NP-C, FPCNA – has no relevant financial relationships to disclose in relation to the content of this activity.

Speaking Faculty:
Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI – has disclosed that he is a consultant for Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Lilly, Janssen, Merck, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; Participation in review activities from CeloNova and St. Jude Medical. His institution, University of Florida, receives grant/research support from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Lilly, Gilead, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions.
Jarett D. Berry, MD – has disclosed that he is a member of the speakers’ bureau for Merck.
Dharam J. Kumbhani, MD, SM, MRCP, FACC, FAHA, FSCAI – has no relevant financial relationships to disclose in relation to the content of this activity.

Peer Reviewers:
Lorrel E. Brown, MD – has no relevant financial relationships to disclose in relation to the content of this activity.
Debra K. Moser, PhD, RN, FAAN – has no relevant financial relationships to disclose in relation to the content of this activity.
Danielle Blais, PharmD, BCPS – has no relevant financial relationships to disclose in relation to the content of this activity.